Results for the Six Months Ended 30 September 2024

Eco Animal Health Group PLC
28 November 2024
 

 

28 November 2024

ECO Animal Health Group plc

Results for the six months ended 30 September 2024

ECO Animal Health Group plc ("ECO", the "Company", or the "Group") (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, today announces its Half Year Report for the six months ended 30 September 2024 in line with the guidance provided in the 1 October 2024 Trading Update.

HIGHLIGHTS

Financial

 

·      Group Revenue decreased 13% to £33.2 million (H1 2023: £38.0 million)

Revenues on a constant currency basis decreased 9%

·      Gross margins 40.3% (H1 2023: 40.8%)

·      Adjusted EBITDA at £0.4 million (H1 2023: £0.7 million)

·      Loss per share of 2.50p (H1 2023: loss per share: 1.93p)

·      Cash generated by operations before working capital increased to £0.8 million (H1 2023: £0.7 million)

·      Cash balances decreased to £18.3 million (30 September 2023 £20.6 million)

 

Operational

 

·      Revenue in USA and Canada increased by 5% to £8.6 million (H1 2023: £8.2 million)

·      Revenue in Latin America increased by 8% to £8.3 million (H1 2023: £7.7 million)

·      Improving pork prices and better producer profitability improved revenues during August and September 2024

·      Rigorous control of input costs has supported gross margins at about the same level as prior year

·      New marketing approval for Aivlosin® in Paraguay

·      Late-stage Mycoplasma vaccine projects for poultry continued to progress towards regulatory submission according to plan, with launches planned for 2025

·      Disposal of non-core equine anti-parasitic product for £1.0 million

 

 

David Hallas, Chief Executive Officer of ECO Animal Health Group plc, commented: "We are encouraged to see an improving revenue performance as we head into the second half of our financial year. As outlined in our trading statement in October, a combination of low disease incidence particularly in China and Southeast Asia, combined with currency headwinds impacted our performance over the summer months. Since then, the Group has seen demand accelerate with 82% of the market consensus* revenue now covered by year-to-date revenue, order books and run rate from the Group's stocking locations. ECO's trading performance is typically second-half weighted and we have observed renewed strength in seasonal trading patterns. This, supported by rigorous cost control, provides confidence that full-year profitability will be in line with market consensus*.

 

"Meanwhile, ECO maintains its targeted focus on its dual future strategy of continuing to support the Aivlosin® franchise and targeted investment in the R&D pipeline, the engine of future growth. The Company believes that over time these investments will generate significant value for shareholders. ECO is on track and expected to deliver value from the R&D pipeline in the next 12 months and continue over the next decade."

 

*           Market consensus for the year ending 31 March 2025 is understood to be revenue of £85 million and EBITDA of £7.2 million

Forward-Looking Statements

 

This announcement contains certain forward-looking statements. The forward-looking statements reflect the knowledge and information available to the Company and Group during preparation  and up to the publication of this announcement. By their very nature, these statements depend upon circumstances and relate to events that may occur in the future and thereby involving a degree of uncertainty. Therefore, nothing in this announcement should be construed as a profit forecast by the Company or Group.

 

 

 

 

Contacts

 

ECO Animal Health Group plc

David Hallas (Chief Executive Officer)

Christopher Wilks (Chief Financial Officer)

 

 


020 8447 8899

ICR Healthcare

Mary-Jane Elliott

Jessica Hodgson

 

 

 

020 3934 6630

 

Singer Capital Markets (Nominated Adviser & Joint Broker)

Phil Davies

Sam Butcher

 

 

 

 

020 7496 3000

Investec (Joint Broker)

Gary Clarence

Lydia Zychowska

 

 

020 7597 5970

 

 

 

 

 

Equity Development

Hannah Crowe

Matt Evans

 

020 7065 2692

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CHAIRMAN AND CHIEF EXECUTIVE'S COMBINED STATEMENT

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024

---

 

The Board is pleased to present the results for the Group for the six months ended 30 September 2024 ("H1 2024"). During the first half of the financial year, the Group experienced continuing sales momentum in key territories despite currency headwinds. In China and Southeast Asia our results were impacted by a slow start to the Summer months in China and the loss of a key customer in Thailand. The Group expects that the typical pattern of demand will result in a significantly stronger second half to our year. The Group's revenue since September 2024, current order books and run rate of sales from the Group's stocking locations provides 82% (H1 2023 - 90%) visibility of full year consensus market forecast revenue*. Control of input costs has supported gross margins at about the same level as prior year and administrative costs have been controlled such that our net profitability is only marginally below. We increased our investment in our promising R&D pipeline and we continued to grow our commercial footprint, gaining a new marketing authorisation for our flagship product Aivlosin® in Paraguay demonstrating the continued strength of the Aivlosin® franchise.

*               Current consensus figures for the year ending 31 March 2025 are £85m of revenue and £7.2m Adjusted EBITDA

 

Financial Performance

Group revenue was 13% lower in H1 2024 at £33.2 million (H1 2023: £38.0 million). China and Japan revenue of £8.2 million represented 25% of Group revenue (H1 2023: 26%). On a constant currency basis, the Group's revenue in H1 2024 was £34.4 million; a decrease of 10% compared with H1 2023. The principal currency effects were from a weaker US Dollar and Chinese RMB compared with Sterling during the period.

The gross margin in H1 2024 was 40.3% (H1 2023: 40.8%). Gross margins were impacted by exchange rate losses but offset by savings in cost of sales.  The Gross margin movement may be analysed as follows:


%

Gross margin in the six months ended 30 September 2023

40.8

F/x impact on revenue

(2.2)

F/x impact on cost of sales

  1.3

Reduction in API costs

1.9

Mix, other

(1.5)

Gross margin in the six months ended 30 September 2024

40.3

           

Administrative expenses excluding foreign exchange gains at £13.4 million were 4.5% lower than the comparative period last year (H1 2023: £14.0 million). This arose in the main from decreased personnel costs (lower bonus accruals, vacancies and f/x savings in US Dollar paid employees). Legal, audit and professional costs were 34% lower than in the prior period due to better credit control leading to lower expected credit loss provisions.

Research and development ("R&D") expense and amounts capitalised were in aggregate a cash investment of £4.1 million (H1 2023: £3.6 million). This represented 12% of revenue generated in the period (H1 2023: 9%).  R&D expensed to the P&L was £2.4 million (H1 2023: £2.1 million); this represented progress in the mid-stage and early pipeline with a number of key proof of concept trials showing good early results. The late-stage Mycoplasma vaccine projects for poultry continued to progress towards regulatory submission according to plan.

Earnings before interest, tax, depreciation, amortisation and impairment, share based payments and foreign exchange movements ("Adjusted EBITDA") were £0.4 million (H1 2023: £0.7 million). This reduction arose as a direct consequence of the lower revenue offset by lower administrative expenses.

As previously announced the Group sold its licences to market an anti-parasitic equine product to its manufacturing partner in Italy.  This sale resulted in a gain of £1.0 million.  This gain is treated as exceptional and not part of the Group's reported Adjusted EBITDA.

Cash generated from operations was £nil (H1 2023: £4.8 million). The underlying cash profits in the period (operating cash flows before movements in working capital) remained strong at £0.8 million (H1 2023: £0.7 million). The unwind of year end trade payables resulted in an adverse movement in working capital.  Inventory remained in line with the year end level and trade receivable showed strong post year end recovery (generating £5.3m cash). Cash balances at 30 September 2024 can be analysed as follows:


At 30 September


2024

(£'m)

2023

(£'m)

Held in UK

6.9

6.1

Held in non-China subsidiaries

1.2

2.9

Held in China 100% owned subsidiary

1.5

1.5

Held in China 51% owned subsidiary

8.7

10.1


18.3

20.6

 

The Group repatriates cash from China by annual dividend declarations; this is subject to withholding taxes of 5% and is paid according to the relevant shareholdings.  On a day‐to‐day basis, the Board considers the cash held in the Group's joint venture subsidiary in China to be unavailable to the Group outside of China; accordingly, cash management and funds available for investment in R&D is based upon the cash balances outside of China.

During June 2024, two dividends totalling £3.0 million (H1 2023: £3.4 million) were received from China.

The Group's committed banking facilities remain at £15.0 million, being a £5.0 million overdraft facility and a £10.0 million revolving credit facility.  These facilities expire on 30 June 2026 and were undrawn as at 30 September 2024.

Basic loss per share in the six months ended 30 September 2024 was 2.50p (H1 2023: loss 1.93p).

Business Performance

The geographical analysis of the Group's revenue in the six months ended 30 September 2024 compared to the prior period in 2023 and the full year ended 31 March 2024 was as follows:

Revenue Summary

6 months ended 30 September


Year ended


2024

2023

H1 24 vs H1 23

31 March 2024


(£'m)

(£'m)

% Change

(£'m)

China and Japan

8.2

9.7

(15%)

24.7

North America (USA and Canada)

8.6

8.2

5%

18.5

South and Southeast Asia

5.1

7.8

(35%)

17.4

Latin America

8.3

7.7

8%

19.9

Europe

2.1

3.4

(38%)

6.5

Rest of World and UK

0.9

1.2

(25%)

2.4

Total Group

33.2

38.0

(13%)

89.4

 

Group revenue decreased by 13% to £33.2 million (H1 2023: £38.0 million). On a constant currency basis the decrease in revenue was 9% in H1 2024 compared with H1 2023. The main components of this overall revenue reduction were China (a reduction of £2.3 million - 27%), Mexico (a reduction of £1.3 million - 44%), Europe (a reduction of £1.3 million - 38%) and South and Southeast Asia (a reduction of £2.7 million - 35%).  Offsetting these falls were gains in Japan (£0.8 million), USA and Canada (£0.4 million), Brazil and other Latin America countries (£1.9 million). 

The lower revenue performance in China was due in the main to low disease incidence during the early summer months of 2024 compared with the equivalent period in 2023 but stronger pork prices and better producer profitability improved revenues during August and September 2024. It is expected that these stronger performances will result in a significantly stronger H2 in China.

The comparative reduction in Mexico revenue in H1 2024 compared with H1 2023 was due to 2023 being particularly strong - inventory shortages in January to March 2023 resulted in strong distributor demand in the first few months of H1 2023.  

The reduction in Europe revenue was mostly due to the withdrawal from Russia (£0.5 million) and the withdrawal from sale of a loss-making product sold in Ireland (£0.5 million). We continue to expect a new licensing approval for Aivlosin® (poultry) in the Kingdom of Saudi Arabia.

The reduction in Southeast Asia arose mainly due to the loss of a key Thailand customer and the change in the distributor in Vietnam resulting in a slow period until the new distributor is appointed. Furthermore, regulatory approval delays in Philippines and Bangladesh have also held this geographical sector back.

The USA, Canada and Japan have traded well due to market share gains, new customer wins and overall market growth.

The macro-economic outlook for the production animal health market remains strong. According to Stonehaven Consulting, pork and poultry consumption is corelated to population growth. Over the past 25 years, consumption of pork and poultry products increased by 70%, rising from 157kTon to 268kTon, compared to population growth of 34% over the same period. With nearly 2 billion more people expected to require more food over the next 25 years, demand for animal protein is set to grow.

Stonehaven Consulting also assessed the animal health product market, revealing a 5-year Compound Annual Growth Rate ("CAGR") of 5.8% in medicated feed additives, 0% for anti-infectives, and 6.4% for vaccines. Notably the disease prevention market, particularly vaccines, is predicted to continue expanding at a CAGR of 3.1% over the next seven years compared with relatively modest growth rate of 1.2% to 1.8% per annum in the disease treatment markets. This further underpins the Group's strategic expansion into vaccines and biologicals whilst recognising that the market remains robust for disease treatment.

Accelerated growth through R&D investment

The Board continues to believe that the R&D portfolio is extremely valuable and will create long-term value for shareholders. The products in our pipeline are highly complementary to our successful existing Aivlosin® based business, addressing the same markets, producers, distributors and diseases. As revenue and profits are generated from these new products the resulting cashflow will be applied in a progressive way to dividend distribution further enhancing shareholder value.

The Group's promising pipeline of new products has continued development according to plan with £4.1 million (H1 2023: £3.6 million) spent during the period. We plan to hold a Capital Markets Day ("CMD") during the final quarter of our financial year; this will follow up on the developments since our last CMD held in November 2023 and provide a status summary of the R&D portfolio.

Preparation for manufacture of the Group's pair of Mycoplasma vaccines for poultry involving technology transfer from the Group's own research lab to the appointed contract manufacturing organisation has been moving ahead and proof of concept trials have been initiated for the necrotic enteritis vaccine for poultry.

Strategy

The Group's strategy is to protect and expand the flagship branded anti-microbial Aivlosin® while making targeted investment in our R&D pipeline of targeted new product development. Our strategy review has endorsed this vision, objectives and pathway. The value in Aivlosin® will be reinforced through further investment in technical and marketing support, while we continue to invest in our valuable R&D pipeline to progress to commercialisation.

Specific priorities have been identified to bring our near to market projects to completion, preparations for their launch are well underway and business partners identified. Defence against generic competition within the Aivlosin® business arena is robust and reinforced with sound technical and marketing initiatives.

The Group is actively pursuing opportunities to collaborate through licencing in or buying new products and licencing out late and mid stage R&D programmes.

Our values

Our values, the "3 C's" of  Curiosity, Commitment and Collaboration are, we believe, the critical success factors which will drive the Group towards achieving its vision.

People

Our people, selected from the best in the animal health industry ensures that the Group's ambitions are achievable.  The alignment of personal values and the Group's values -are central to employee engagement. The Group is proud of its social and charitable initiatives, particularly as many of these are employee led.  The Board wishes to thank our people for their continuing diligence, active engagement and effort throughout the period.

Outlook

The Group expects that the historically observed increased demand for Aivlosin® associated with the Northern Hemisphere winter will once again result in a stronger second half to our year. 82% of the market consensus revenue is covered by year-to-date revenue, order books and run rate from the Group's stocking locations.  Additionally, the first half currency headwinds have normalised and the phasing and mix of revenues, inventory usage and costs all support the forward profitability. The Board will continue during the remainder of this financial year to invest in our exciting new product pipeline and pursue options to realise value.

The Board looks forward with cautious optimism to reporting the full year numbers in line with revised market expectations.

 

Dr Andrew Jones                                                      David Hallas

Chairman                                                                   Chief Executive Officer



 

CONSOLIDATED INCOME STATEMENT

 






Six months to 30.09.24 (unaudited)

Six months to 30.09.23 (unaudited)

Year ended 31.03.24 (audited)

 

Notes

£000's

£000's

£000's

 





Revenue

6

33,182

38,009

89,422

Cost of sales


(19,818)

(22,508)

(51,739)

Gross profit

 

13,364

15,501

37,683

 


40.3%

40.8%

42.1%






Administrative expenses


(13,388)

(14,016)

(29,394)

Research and development expenses


(2,350)

(2,098)

(4,169)

Other income


148

29

66

Exceptional items

7

1,046

-

(651)

Operating (loss)/profit

 

(1,180)

(584)

 





Share of profit of associate


40

47

53

Finance income


59

76

150

(Loss)/profit before financing and income tax

 

(1,081)

(461)

 





Finance costs


(336)

(166)

(764)

(Loss)/profit before income tax

 

(1,417)

(626)

2,974

 





Income tax charge

9

(343)

(580)

(966)

(Loss)/profit for the year

 

(1,760)

(1,206)

2,008

 





(Loss)/profit attributable to:

 




Owners of the parent Company


(1,697)

(1,307)

1,048

Non-controlling interest


(63)

101

960

(Loss)/profit for the year

 

(1,760)

(1,206)

2,008

 





(Loss)/earnings per share (pence)

8

(2.50)

(1.93)

1.55






Diluted (loss)/earnings per share (pence)

8

(2.50)

(1.93)

1.52






Adjusted EBITDA (Non-GAAP measure)

6

445

705

8,046

 

 

 

 

 



 

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME



Six months to 30.09.24 (unaudited)

Six months to 30.09.23 (unaudited)

Year ended 31.03.24 (audited)

 


£000's

£000's

£000's

 





(Loss)/profit for the year

 

(1,760)

(1,206)

2,008

 





Other comprehensive loss:

 









Items that may be reclassified to profit or loss:

 




Foreign currency translation differences


(240)

(1,285)

(1,828)






Items that will not be reclassified to profit or loss:

 




Remeasurement of defined benefit pension schemes


-

-

43

Other comprehensive loss for the year

 

(240)

(1,285)

(1,785)

 





Total comprehensive (loss)/income for the year

 

(2,000)

(2,491)

223

 





Attributable to:

 




Owners of the parent Company


(1,684)

(2,070)

1

Non-controlling interest


(316)

(421)

222



(2,000)

(2,491)

223

 

 

 

 



 

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY














Share Capital

Share Premium

Revaluation Reserve

Other Reserves

Foreign Exchange Reserve

Retained Earnings

Total

Non-controlling Interest

Total Equity

 

£000's

£000's

£000's

£000's

£000's

£000's

£000's

£000's

£000's

Balance at 31 March 2023

3,381

63,319

657

106

1,878

13,929

83,270

12,281

95,551

Profit for the year

-

-

-

-

-

1,048

1,048

960

2,008

Other comprehensive income:










Foreign currency differences

-

-

-

-

(1,090)

-

(1,090)

(738)

(1,828)

Actuarial gains on pension
scheme assets

-

-

-

-

-

43

43

-

43

Total comprehensive income for the year

-

-

-

-

(1,090)

1,091

1

222

223

Transactions with owners:










Issue of shares in the year

6

-

-

-

-

-

6

-

6

Revaluation reserve

-

-

(386)

-

-

386

-

-

0

Share-based payments

-

-

-

-

-

413

413

-

413

Dividends

-

-

-

-

-

-

-

(2,813)

(2,813)

Transactions with owners

6

-

(386)

-

-

799

419

(2,813)

(2,394)

Balance at 31 March 2024

3,387

63,319

271

106

788

15,819

83,690

9,690

93,380

 










Loss for the period

-

-

-

-

-

(1,697)

(1,697)

(63)

(1,760)

Other comprehensive income:










Foreign currency differences

-

-

-

-

13

-

13

(253)

(240)

Total comprehensive income for the period

-

-

-

-

13

(1,697)

(1,684)

(316)

(2,000)

Transactions with owners:










Share-based payments

-

-

-

-

-

186

186

-

186

Dividends

-

-

-

-

-

-

-

(1,065)

(1,065)

Transactions with owners

-

-

-

-

-

186

186

(1,065)

(879)

Balance at 30 September 2024

3,387

63,319

271

106

801

14,308

82,192

8,309

90,501

 

 

 



 

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

 






 











 


Share Capital

Share Premium

Revaluation Reserve

Other Reserves

Foreign Exchange Reserve

Retained Earnings

Total

Non-controlling Interest

Total Equity

 

 

£000's

£000's

£000's

£000's

£000's

£000's

£000's

£000's

£000's

 

Balance as at 31 March 2022

3,381

63,319

657

106

2,188

12,413

82,064

12,284

94,348

 

Profit for the year

-

-

-

-

-

1,008

1,008

2,083

3,091

 

Other comprehensive income:










Foreign currency movement

-

-

-

-

(310)

-

(310)

(276)

(586)

 

Actuarial gains on pension
scheme assets

-

-

-

-

-

100

100

-

100

 

Total comprehensive income for the year

-

-

-

-

(310)

1,108

798

1,807

2,605

 

Transactions with owners:










Share-based payments

-

-

-

-

-

408

408

-

408

 

Dividends

-

-

-

-

-

-

-

(1,810)

(1,810)

 

Transactions with owners

-

-

-

-

-

408

408

(1,810)

(1,402)

 

Balance as at 31 March 2023

3,381

63,319

657

106

1,878

13,929

83,270

12,281

95,551

 

 










 

Loss for the period

-

-

-

-

-

(1,307)

(1,307)

101

(1,206)

 

Other comprehensive income:










Foreign currency movement

-

-

-

-

(763)

-

(763)

(522)

(1,285)

 

Total comprehensive loss for the period

-

-

-

-

(763)

(1,307)

(2,070)

(421)

(2,491)

 

Transactions with owners:










Issue of shares in the year

1

-

-

-

-

-

1

-

1

 

Share-based payments

-

-

-

-

-

320

320

-

320

 

Dividends

-

-

-

-

-

-

-

(2,814)

(2,814)

 

Transactions with owners

1

-

-

-

-

320

321

(2,814)

(2,493)

 

Balance at 30 September 2023

3,382

63,319

657

106

1,115

12,942

81,521

9,046

90,567

 

 

 


 

 



 

CONSOLIDATED STATEMENT OF FINANCIAL POSITION



Group

 


As at 30.09.24 (unaudited)

As at 30.09.23 (unaudited)

As at 31.03.24 (audited)

 

Notes

£000's

£000's

£000's

 





Non-current assets

 




Intangible assets

10

39,561

36,639

38,351

Property, plant and equipment


4,296

5,834

4,802

Right-of-use assets


3,274

3,857

3,672

Investments


310

274

268

Deferred tax assets


1,316

579

1,437

Total non-current assets

 

48,757

47,183

48,530

 





Current assets

 




Inventories


16,745

19,497

16,955

Trade and other receivables


26,778

25,748

32,175

Income tax recoverable


991

1,647

2,687

Other taxes and social security


160

461

526

Cash and cash equivalents


18,298

20,577

22,374

Assets held for sale


-

230

18

Total current assets

 

62,972

68,160

74,735

TOTAL ASSETS

 

111,729

115,343

123,265

 





Current Liabilities

 




Trade and other payables


(10,826)

(15,020)

(17,353)

Provisions


(5,143)

(5,301)

(5,859)

Income tax payable


30

(116)

(687)

Other taxes and social security payable


(306)

(151)

(632)

Lease liabilities


(574)

(934)

(646)

Dividends


(50)

(50)

(50)

Total current liabilities

 

(16,869)

(21,572)

(25,227)

Net current assets

 

46,103

46,588

49,508

Total assets less current liabilities

 

94,860

93,771

98,038

 





Non-current liabilities

 




Deferred tax liabilities


(1,279)

-

(1,279)

Lease liabilities


(3,080)

(3,204)

(3,379)

TOTAL ASSETS LESS TOTAL LIABILITIES

 

90,501

90,567

93,380

 





EQUITY

 




Issued share capital


3,387

3,382

3,387

Share premium account


63,319

63,319

63,319

Revaluation reserve


271

657

271

Other reserves


106

106

106

Foreign exchange reserve


801

1,115

788

Retained earnings


14,308

12,942

15,819

Shareholders' funds


82,192

81,521

83,690

Non-controlling interests


8,309

9,046

9,690

TOTAL EQUITY

 

90,501

90,567

93,380

 

 

 

 



 

Consolidated Cash Flow Statement

 






Group

 


Six months to 30.09.24 (unaudited)

Six months to 30.09.23 (unaudited)

Year ended 31.03.24 (audited)

 


£000's

£000's

£000's

Cash flows from operating activities

 




(Loss)/Profit before income tax


(1,417)

(627)

2,974

Adjustment for:

 




Finance income


(59)

(76)

(150)

Finance cost


336

166

764

Foreign exchange (gain)/loss


1,158

(219)

572

Depreciation


451

452

958

Amortisation of right-of-use assets


316

203

683

Amortisation of intangible assets


560

533

1,154

Impairment of right-of-use assets


-

-

80

Share of associate's results


(40)

(47)

(53)

Share based payment charge


186

320

413

Exceptional items


(736)

-

306

Operating cash flows before movements in working capital

 

755

705

 





(Increase)/decrease in inventory


(153)

2,535

4,741

Decrease/(increase) in receivables


5,298

2,349

(4,961)

(Decrease)/increase in payables


(5,571)

(793)

2,456

(Decrease)/increase in provision and pensions


(333)

16

554

Cash (used in)/generated from operations

 

(4)

4,812

 





Finance costs


(130)

(6)

(473)

Income tax


627

(135)

(601)

Net cash from/(used in) operations

 

493

4,671

9,417

 





Cash flows from investing activities

 




Acquisition of property, plant and equipment


(100)

(386)

(502)

Proceeds from sale of property, plant and equipment


-

-

1,058

Purchase of intangibles


(1,769)

(1,536)

(4,122)

Proceeds from sale of horse paste business


380

-

-

Finance income


59

76

150

Net cash (used in)/from investing activities

 

(1,430)

(1,846)

(3,416)

 





Cash flows from financing activities

 




Proceeds from issue of share capital


-

1

6

Interest paid on lease liabilities


(206)

(160)

(291)

Principal paid on lease liabilities


(282)

(112)

(593)

Dividends paid


(1,065)

(2,813)

(2,813)

Net cash used in financing activities

 

(1,553)

(3,084)

(3,691)

Net (decrease)/increase in cash and cash equivalents

 

(2,490)

(259)

2,310

Foreign exchange movements


(1,586)

(822)

(1,594)

Balance at the beginning of the period


22,374

21,658

21,658

Balance at the end of the period


18,298

20,577

22,374



NOTES TO THE PRELIMINARY RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2024

---

1.             General information

 

ECO Animal Health Group plc ("the Company") and its subsidiaries (together "the Group") manufacture and supply animal health products globally.

 

The Company is traded on the AIM market of the London Stock Exchange and is incorporated and domiciled in the UK. The address of its registered office is The Grange, 100 High Street, Southgate, London, N14 6BN.

 

2.             Summary of the Group's significant accounting policies

 

2.1          Basis of preparation

 

The financial information for the period to 30 September 2024 does not constitute statutory accounts as defined by Section 435 of the Companies Act 2006. It has been prepared in accordance with the accounting policies set out in, and is consistent with, the audited financial statements for year ended 31 March 2024.

 

This Interim Statement has not been audited or reviewed by the Group's auditors.

 

2.2          Statement of compliance

 

This Interim Statement is prepared in accordance with IAS 34 "Interim Financial Reporting". Accordingly, whilst the Interim Statement has been prepared in accordance with IFRS, and the primary statements follow the format of the annual financial statements, only selected notes are included - those that provide an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of the Group since the last annual reporting date. IAS 34 states a presumption that anyone who reads the Group's Interim Statement will also have access to its most recent annual report. Accordingly, annual disclosures are not repeated in this Interim Statement.

 

3.     Changes to significant accounting policies and other restatements

The principal accounting policies which are adopted by the Group in the preparation of its financial statements are set out in in the consolidated financial statements of the Group for the year ended 31 March 2024. These policies have been consistently applied to all prior years. The Group's accounting policies have been consistently applied in accordance with IFRS continued into the six months ended 30 September 2024.

 

As set out in the consolidated financial statements of the Group for the year ended 31 March 2024, new standards and amendments came into effect during the financial year. These standards and amendments do not have a material impact.

 

4.             Revenue

 

Revenue is derived from the Group's animal pharmaceutical businesses.

 

5.             Principal risks and uncertainties

 

The principal risks and uncertainties relating to the Group were set out on pages 10-13 of the Group's Annual Report and Accounts for the year ended 31 March 2024. The key exposures identified at 31 March 2024 were: a high dependency on a single product, potential threat from generic producers, multiple new product launches in a single year, quality risk regarding new biologicals manufacturing, foreign currency exchange rates, disease impact on growth, the risk that tech transfer from R&D to manufacture fails or is delayed, and recession in major regions of the world leading to reduced demand for the Group's products.  These risks have remained unchanged since the year end.

 

.



 

6.             Segment information

 

Management has determined the operating segments based on the reports reviewed by the Board to make strategic decisions. The Board considers the business from a geographical perspective. Geographically, management considers the performance in the Corporate/UK, China and Japan, North America, South and Southeast Asia, Latin America, Europe and the Rest of the World.

 

Revenues are geographically allocated by the destination of customer.

 

The performance of these geographical segments is measured using Earnings before Interest, Tax, Depreciation, Amortisation and exceptional items adjusted to exclude share-based payments and impairment ("Adjusted EBITDA" and is referred to in the table below). Adjusted EBITDA is a non-GAAP measure used by the business to assess the underlying business performance.

 


Corporate
/UK

China & Japan

North America

S & SE Asia

Latin America

Europe

Rest of World

Total

 

£000's

£000's

£000's

£000's

£000's

£000's

£000's

£000's

Six months to 30.09.24 (unaudited)

 








Sale of goods

583

8,164

8,594

5,079

8,334

2,145

283

33,182

Royalties

-

-

-

-

-

-

-

-

Revenue from external customers

583

8,164

8,594

5,079

8,334

2,145

283

33,182










Adjusted EBITDA

(7,856)

1,827

2,384

1,723

540

531

138

(713)










Six months to 30.09.23 (unaudited)

 








Sale of goods

503

9,705

8,193

7,746

7,722

3,481

562

37,912

Royalties

-

-

-

-

-

-

97

97

Revenue from external customers

503

9,705

8,193

7,746

7,722

3,481

659

38,009










Adjusted EBITDA

(8,363)

1,948

3,267

2,591

763

364

354

925










Year ended 31 March 2024

 








Sale of goods

925

24,656

18,480

17,440

19,891

6,452

1,529

89,373

Royalties

-

-

-

-

-

-

49

49

Revenue from external customers

925

24,656

18,480

17,440

19,891

6,452

1,578

89,422










Adjusted EBITDA

(17,281)

7,007

7,229

5,612

3,578

488

842

7,474

 

 

 

A reconciliation of Adjusted EBITDA for reportable segments to profit from operating activities is provided as follows:

 



Six months to 30.09.24 (unaudited)

Six months to 30.09.23 (unaudited)

Year ended 31.03.24 (audited)

 


£000's

£000's

£000's

Adjusted EBITDA for reportable segments

 



(713)

925

7,474

Depreciation




(451)

(452)

(958)

Amortisation of right-of-use assets




(316)

(204)

(683)

Amortisation




(560)

(533)

(1,154)

Impairment of right-of-use assets




-

-

(80)

Exceptional items




1,046

-

(651)

Share-based payment charges




(186)

(320)

(413)

Profit from operating activities




(1,180)

(584)

3,535








Foreign exchange differences




1,158

(220)

572

Adjusted EBITDA for the Group




445

705

8,046

 

 

 

 

 

 

 

 

7.             Exceptional items




Six months to 30.09.24 (unaudited)

Six months to 30.09.23 (unaudited)

Year ended 31.03.24 (audited)

 



£000's

£000's

£000's

Cessation of distribution business



-

-

(933)

Profit on disposal of properties



-

-

282

Disposal of equine anti parasitic product line



1,046

-

-




1,046

-

(651)

 

 

8.             (Loss)/earnings per share

 

The calculation of basic earnings per share is based on the post-tax profit for the year divided by the weighted average number of shares in issue during the year.

 

 


Six months to 30.09.24 (unaudited)

 


Six months to 30.09.23 (unaudited)

 


Year ended 31.03.24 (audited)

 

Earnings

Weighted average number of shares

Per share amount

 

Earnings

Weighted average number of shares

Per share amount

 

Earnings

Weighted average number of shares

Per share amount

 

£000's

000's

pence

 

£000's

000's

pence

 

£000's

000's

pence

 












Earnings attributable to ordinary shareholders on continuing operations after tax

(1,697)

67,745

(2.50)


(1,307)

67,722

(1.93)


1,048

67,745

1.55

Dilutive effect of share options

-

-

-


-

-

-


-

1,335

-

Diluted earnings per share

(1,697)

67,745

(2.50)


(1,307)

67,722

(1.93)


1,048

69,080

1.52

 

 

 

The diluted EPS figure reflects the impact of historic grants of share options and is calculated by reference to the number of options granted for which the average share price for the year was in excess of the option exercise price. As the Group's result for the six months ended 30 September 2024 was loss, there was no dilutive effect on the earnings per share in this period.

 

 

9.             Taxation

 

The effective rate of the tax charge in the six months to 30 September 2024 is minus 22% which is lower than the effective rate in the six months to 30 September 2023 of 93%. The effective rate reflects the impact of tax losses incurred without recognising a corresponding deferred tax asset and of withholding taxes suffered on dividends received during the period. 



 

10.          Intangible assets

 

Group

Goodwill

Distribution rights

Drug registrations, patents and licence costs

Total

 

£000's

£000's

£000's

£000's

Cost

 




At 31 March 2023

17,930

407

25,711

44,048

Additions

-

-

1,536

1,536

At 30 September 2023

17,930

407

27,247

45,584

At 31 March 2023

-

-

2,567

2,567

Disposal

-

-

(268)

(268)

At 31 March 2024

17,930

407

29,546

47,883

Additions

-

-

1,770

1,770

At 30 September 2024

17,930

407

31,316

49,653

 





Amortisation

 




At 31 March 2023

-

(178)

(8,234)

(8,412)

Charge for the period

-

(10)

(523)

(533)

At 30 September 2023

-

(188)

(8,757)

(8,945)

Charge for the period

-

(10)

(577)

(587)

At 31 March 2024

-

(198)

(9,334)

(9,532)

Charge for the period

-

(10)

(550)

(560)

At 30 September 2024

-

(208)

(9,884)

(10,092)

 





Net book value

 




At 30 September 2024

17,930

199

21,432

39,561

At 31 March 2024

17,930

209

20,212

38,351

At 30 September 2023

17,930

219

18,490

36,639

At 31 March 2023

17,930

229

17,477

35,636

 

 

The amortisation and impairment charges are included within administrative expenses in the income statement.

 

The Group continuously reviews the status of its research and development activity, paying close attention to the likelihood of technical success and the commercial viability of development projects. In the period to September 2024 there were no indications that any development projects for which costs have previously been capitalised were unlikely to achieve technical success or commercial viability.

 

11.  Related party transactions

 

Interest and management charges from Parent to the other Group companies

 

During the period Zhejiang ECO Animal Health Ltd paid dividends of £1,860,759 (RMB 17,118,983) to ECO Animal Health Ltd (H1 2023: £449,600).

 

During the period Zhejiang ECO Biok Animal Health Products Limited paid dividends of £85,217 (RMB 784,000) to ECO Animal Health Group plc (H1 2023: £225,029) and £1,023,478 (RMB 9,416,000) to ECO Animal Health Limited (H1 2023: £2,702,641).

 

This financial information was approved by the Board on 27 November 2024.

This interim statement is available on the Group's website.

 

DIRECTORS AND OFFICERS

Dr Andrew Jones

David Hallas

Chris Wilks

Tracey James

Dr Frank Armstrong

Joachim Hasenmaier

(Non-Executive Chairman)

(Chief Executive Officer)

(Chief Financial Officer)

(Non-Executive Director)

(Non-Executive Director)

(Non-Executive Director)




REGISTERED OFFICE

The Grange, 100 High Street, Southgate, London, N14 6BN

Tel: 020 8447 8899



COMPANY NUMBER

01818170





INFORMATION AT

www.ecoanimalhealth.com


 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100